504 related articles for article (PubMed ID: 24366995)
1. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
[TBL] [Abstract][Full Text] [Related]
3. Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).
Knutsen AP; Leiva LE; Caruthers C; Rodrigues J; Sorensen RU
Clin Exp Immunol; 2015 Oct; 182(1):51-6. PubMed ID: 26230522
[TBL] [Abstract][Full Text] [Related]
4. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
7. Serial Serum Immunoglobulin G (IgG) Trough Levels in Patients with X-linked Agammaglobulinemia on Replacement Therapy with Intravenous Immunoglobulin: Its Correlation with Infections in Indian Children.
Suri D; Bhattad S; Sharma A; Gupta A; Rawat A; Sehgal S; Singh S; Gupta S
J Clin Immunol; 2017 Apr; 37(3):311-318. PubMed ID: 28321612
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
9. Home self-administration of intravenous immunoglobulin therapy in children.
Kobayashi RH; Kobayashi AD; Lee N; Fischer S; Ochs HD
Pediatrics; 1990 May; 85(5):705-9. PubMed ID: 2109852
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
11. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.
Costa-Carvalho BT; Sullivan KE; Fontes PM; Aimé-Nobre F; Gonzales IGS; Lima ES; Granato C; de Moraes-Pinto MI
J Clin Immunol; 2018 Jul; 38(5):628-634. PubMed ID: 30006913
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
13. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
14. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy.
Adam E; Church JA
J Clin Immunol; 2015 Feb; 35(2):213-7. PubMed ID: 25631528
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
16. Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections.
Hidalgo H; Moore C; Leiva LE; Sorensen RU
Ann Allergy Asthma Immunol; 1996 Apr; 76(4):341-6. PubMed ID: 8612116
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
18. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
Rojavin MA; Hubsch A; Lawo JP
J Clin Immunol; 2016 Apr; 36(3):210-9. PubMed ID: 26910102
[TBL] [Abstract][Full Text] [Related]
20. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
